Antiangiogenic drugs in ovarian cancer

Ovarian cancer continues to be a major cause of morbidity and mortality in women. Antiangiogenic treatments have emerged as a promising strategy to treat ovarian cancer. This article reviews the rationale supporting the use of antiangiogenic treatments in ovarian cancer, the clinical development of...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumaran, G C, Jayson, G C, Clamp, A R
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2009
Materias:
Minireview
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2634670/
https://www.ncbi.nlm.nih.gov/pubmed/19002176
http://dx.doi.org/10.1038/sj.bjc.6604767
Descripción
Sumario:Ovarian cancer continues to be a major cause of morbidity and mortality in women. Antiangiogenic treatments have emerged as a promising strategy to treat ovarian cancer. This article reviews the rationale supporting the use of antiangiogenic treatments in ovarian cancer, the clinical development of this group of drugs and the toxicities specific to this modality of treatment.

Ejemplares similares